Pfizer Inc. (PFE)
Pfizer struggles to claw back faith with Wall Street and its employees as it recovers from the Covid decline
Pfizer appears to be on its way toward stabilizing its business and winning back Wall Street's favor after the sudden decline of its Covid business. But the company is struggling to balance that with the concerns and fears of its workers.
Is Pfizer Stock a Buy?
Pfizer shares have suffered a painful slide as pandemic revenue dried up. But management is committed to maintaining and growing the dividend.
2 Healthcare Stocks That Are Screaming Buys in June
A rare-disease drugmaker and a top pharmaceutical stock have what it takes to deliver solid returns over the long run. Vertex Pharmaceuticals' flagship business continues to expand market share and profits.
This Recent FDA Approval Is Bad News for Pfizer
Pfizer dominates the pneumococcal vaccine market. However, Merck has obtained approval for a pneumococcal vaccine Merck's new medication could become the new top seller for this indication.
Is Pfizer's Pain Sarepta Therapeutics' Gain? Don't Bet on It.
Pfizer just whiffed one of its late-stage clinical trials. Sarepta Therapeutics just got regulators to sign off on a similar program.
Pfizer (PFE) Stock Sinks As Market Gains: Here's Why
Pfizer (PFE) closed at $27.99 in the latest trading session, marking a -1.3% move from the prior day.
Pfizer's Working on the Next Wegovy, but Can It Beat Novo Nordisk?
Novo Nordisk is raking in billions from Ozempic and Wegovy. Pfizer wants in on the action, so it's teaming up with a biotech.
2 Beaten-Down Growth Stocks to Buy Without Hesitation in the 2024 Bull Market
Healthcare and beauty are both explosive industries -- and potential hunting grounds for good stocks. Pfizer is navigating the aftermath of its pandemic successes, but a much brighter future could be just ahead.
Pfizer: Seriously Undervalued At Peak Pessimism
Since the publication of my last article, Pfizer has continued to surprise me pleasantly. In early May, Pfizer published financial results for the first quarter of 2024, which were enthusiastically received by Wall Street. On June 14, 2024, the company announced promising results from a Phase 2 clinical trial, again demonstrating the clinical benefit of Elrexfio in the treatment of relapsed or refractory multiple.
Want an Extra $100 in Annual Dividend Income? Invest $1,320 in These 3 High-Yield Stocks
AT&T's dividend hasn't risen in a while due to a heavy debt load, but there could be plenty of progress in the years ahead. With a dividend yield above 10% at recent prices, PennantPark Floating Rate Capital can produce market-beating gains by holding its monthly payment steady over the long run.
Investing for the Next 12 Months? Buy These
If investors expect interest rates to hold until next year, they should consider dividend-yielding stocks like Altria (NYSE: MO), Bristol Myers, and Pfizer (NYSE: PFE), which offer reasonable values and attractive yields.
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
